Biohaven Ltd. (BHVN) Securities Fraud Investigation - Levi & Korsinsky
NEW YORK CITY, NY / ACCESS Newswire / September 11, 2026 /Levi & Korsinsky notifies investors that it has commenced an investigation into Biohaven Ltd. ("Biohaven Ltd.") (NYSE:BHVN) concerning potential violations of the federal securities laws.
Biohaven Ltd. shares fell 14.73% on September 10, 2026, following a partial clinical hold issued by the FDA on the Company 's BHV-7000/opakalim program, pausing new patient enrollment. The FDA reportedly "determined that there was insufficient information related to a specific metabolite to assess risks" of a "certain metabolites of BHV-7000 observed in rodent testing." This follows the August 26 announcement of a licensing agreement for Biohaven 's Kv7 ion channel platform, led by opakalim.
If you suffered a loss on your Biohaven Ltd. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY:Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services ' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
SOURCE:Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire
© 2026 ACCESS Newswire. All Rights Reserved.
